» Articles » PMID: 38833182

The Immune System in Parkinson's Disease: What We Know So Far

Abstract

Parkinson's disease is characterized neuropathologically by the degeneration of dopaminergic neurons in the ventral midbrain, the accumulation of α-synuclein (α-syn) aggregates in neurons and chronic neuroinflammation. In the past two decades, in vitro, ex vivo and in vivo studies have consistently shown the involvement of inflammatory responses mediated by microglia and astrocytes, which may be elicited by pathological α-syn or signals from affected neurons and other cell types, and are directly linked to neurodegeneration and disease development. Apart from the prominent immune alterations seen in the CNS, including the infiltration of T cells into the brain, more recent studies have demonstrated important changes in the peripheral immune profile within both the innate and adaptive compartments, particularly involving monocytes, CD4+ and CD8+ T cells. This review aims to integrate the consolidated understanding of immune-related processes underlying the pathogenesis of Parkinson's disease, focusing on both central and peripheral immune cells, neuron-glia crosstalk as well as the central-peripheral immune interaction during the development of Parkinson's disease. Our analysis seeks to provide a comprehensive view of the emerging knowledge of the mechanisms of immunity in Parkinson's disease and the implications of this for better understanding the overall pathogenesis of this disease.

Citing Articles

RGS10 attenuates systemic immune dysregulation induced by chronic inflammatory stress.

Jernigan J, Staley H, Baty Z, Bolen M, Gomes B, Holt J J Neuroinflammation. 2025; 22(1):49.

PMID: 39994765 PMC: 11852585. DOI: 10.1186/s12974-024-03322-1.


Editorial: Function and regulation of non-neuronal cells in the nervous system.

Li S, Cai Y, Xia Z Front Cell Neurosci. 2025; 19:1550903.

PMID: 39990969 PMC: 11842420. DOI: 10.3389/fncel.2025.1550903.


Emodin, a Potent Anthraquinone Mitigates MPTP-Induced Parkinsons' Disease Pathology by Regulating Nrf2 and Its Downstream Targets: In Silico and In Vivo Approach.

Jahan S, Ikram M, Siraj S, Ullah S, Zakria M, Ahmad N Mol Neurobiol. 2025; .

PMID: 39976808 DOI: 10.1007/s12035-025-04762-3.


IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease - IMMUPARKNET.

Gugu M, Acharya S, Pira D, Poletti S, di Flora A, Saksida T Open Res Eur. 2025; 4:119.

PMID: 39911303 PMC: 11795026. DOI: 10.12688/openreseurope.17547.2.


Design, synthesis, and anti-inflammatory activity of 2H-1,4-benzoxazin-3(4H)-one derivatives modified with 1,2,3-triazole in LPS-induced BV-2 cells.

Hou X, Mao L, Zhang H, Wang L, He B, Guo J Front Pharmacol. 2025; 15:1509520.

PMID: 39902072 PMC: 11788571. DOI: 10.3389/fphar.2024.1509520.


References
1.
Contaldi E, Magistrelli L, Cosentino M, Marino F, Comi C . Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio Are Associated with Mild Cognitive Impairment in Parkinson's Disease: A Single-Center Longitudinal Study. J Clin Med. 2022; 11(19). PMC: 9571051. DOI: 10.3390/jcm11195543. View

2.
Ho D, Nam D, Seo M, Park S, Seol W, Son I . LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells. 2022; 11(5). PMC: 8909553. DOI: 10.3390/cells11050861. View

3.
Zhou Y, Lu M, Du R, Qiao C, Jiang C, Zhang K . MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol Neurodegener. 2016; 11:28. PMC: 4833896. DOI: 10.1186/s13024-016-0094-3. View

4.
Ip C, Beck S, Volkmann J . Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. J Neural Transm (Vienna). 2015; 122(12):1633-43. DOI: 10.1007/s00702-015-1444-y. View

5.
Volc D, Poewe W, Kutzelnigg A, Luhrs P, Thun-Hohenstein C, Schneeberger A . Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020; 19(7):591-600. DOI: 10.1016/S1474-4422(20)30136-8. View